Biological Basis of Novel Therapies for Myelodysplastic Syndrome

Author(s): Eyal C. Attar, Karen K. Ballen

Journal Name: Current Cancer Therapy Reviews

Volume 2 , Issue 3 , 2006

Become EABM
Become Reviewer


Myelodysplastic syndrome (MDS) represents a group of malignant clonal disorders characterized by ineffective hematopoiesis and an accumulation of hematopoietic precursors in the bone marrow, frequently resulting in transformation to acute leukemia and death. However, recent understanding of MDS pathophysiology has provided novel treatment approaches with pharmacologic agents capable of manipulating pathways intrinsic and extrinsic to the malignant hematopoietic clone. These advances provide new therapeutic options for patients and provide a basis for further understanding and treatment of this disease.

Keywords: Myelodysplastic syndrome, myeloid, apoptosis, cell cycle, 5q-, cancer stem cell

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [199 - 209]
Pages: 11
DOI: 10.2174/157339406777934708
Price: $65

Article Metrics

PDF: 2